Effects of apraclonidine on aqueous humor dynamics in human eyes - PubMed (original) (raw)
Clinical Trial
Effects of apraclonidine on aqueous humor dynamics in human eyes
C B Toris et al. Ophthalmology. 1995 Mar.
Abstract
Purpose: The mechanism by which apraclonidine, an alpha 2-adrenergic agonist, lowers intraocular pressure (IOP) was evaluated in humans.
Methods: In a randomized, double-masked, placebo-controlled study, 0.5% apraclonidine was given topically twice daily for 1 week to one eye in each of 21 ocular hypertensive volunteers. The other eye was treated similarly with vehicle. Before and after 1 week of treatment, aqueous flow, uveoscleral outflow, fluorophotometric outflow facility, intraocular pressure, tonographic outflow facility, episcleral venous pressure, and outflow pressure were either directly measured or mathematically calculated. Values were compared in treated versus contralateral control eyes and on baseline versus day 8 of treatment.
Results: When compared with both contralateral control eyes and baseline day, fluorophotometric outflow facility in the apraclonidine-treated eyes increased by 0.09 to 0.10 microliter/minute/mmHg (P < 0.04), IOP decreased by 3.1 to 5.2 mmHg (P < 0.0001), and outflow pressure decreased by 3.3 to 4.2 mmHg (P < 0.0001). When compared with baseline day only, aqueous flow in the apraclonidine-treated eyes decreased by 0.3 microliter/minute (P < 0.04), and episcleral venous pressure decreased by 1.0 mmHg (P < 0.001). Episcleral venous pressure also decreased in the control eyes compared with baseline day by 1.3 mmHg (P < 0.001). When compared with contralateral control eyes only, uveoscleral outflow in the apraclonidine-treated eyes decreased by 0.47 microliter/minute (P < 0.03). Tonographic outflow facility showed no change when compared with either contralateral control eyes or baseline values.
Conclusions: The apraclonidine-induced reduction in intraocular pressure was associated with an increase in fluorophotometric outflow facility, decrease in aqueous flow and decrease in episcleral venous pressure compared to baseline. The lack of a significant difference in aqueous flow and episcleral venous pressure between treated and contralateral control eyes may represent a contralateral drug effect.
Similar articles
- Effects of brimonidine on aqueous humor dynamics in human eyes.
Toris CB, Gleason ML, Camras CB, Yablonski ME. Toris CB, et al. Arch Ophthalmol. 1995 Dec;113(12):1514-7. doi: 10.1001/archopht.1995.01100120044006. Arch Ophthalmol. 1995. PMID: 7487618 Clinical Trial. - Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.
Toris CB, Camras CB, Yablonski ME. Toris CB, et al. Ophthalmology. 1993 Sep;100(9):1297-304. doi: 10.1016/s0161-6420(93)31484-3. Ophthalmology. 1993. PMID: 8371915 Clinical Trial. - Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.
Toris CB, Camras CB, Yablonski ME. Toris CB, et al. Am J Ophthalmol. 1999 Jul;128(1):8-14. doi: 10.1016/s0002-9394(99)00076-8. Am J Ophthalmol. 1999. PMID: 10482088 Clinical Trial. - Mechanism of action of bimatoprost (Lumigan).
Brubaker RF. Brubaker RF. Surv Ophthalmol. 2001 May;45 Suppl 4:S347-51. doi: 10.1016/s0039-6257(01)00213-2. Surv Ophthalmol. 2001. PMID: 11434937 Review. - Preclinical evaluation of brimonidine.
Burke J, Schwartz M. Burke J, et al. Surv Ophthalmol. 1996 Nov;41 Suppl 1:S9-18. doi: 10.1016/s0039-6257(96)82027-3. Surv Ophthalmol. 1996. PMID: 8970245 Review.
Cited by
- Safety threshold of intravitreal clonidine in rabbit's eyes.
Nikkhah H, Garfami KH, Kanavi MR, Nashtaei EM, Karimi S, Soheilian M. Nikkhah H, et al. Int J Ophthalmol. 2018 Jan 18;11(1):25-30. doi: 10.18240/ijo.2018.01.05. eCollection 2018. Int J Ophthalmol. 2018. PMID: 29375986 Free PMC article. - Effectiveness of apraclonidine 1% in preventing intraocular pressure rise following macular hole surgery.
Sciscio A, Casswell AG. Sciscio A, et al. Br J Ophthalmol. 2001 Feb;85(2):164-8. doi: 10.1136/bjo.85.2.164. Br J Ophthalmol. 2001. PMID: 11159479 Free PMC article. Clinical Trial. - [General substance classification and pharmacology of glaucoma].
Thieme H, Renieri G, Schuart C. Thieme H, et al. Ophthalmologe. 2013 Dec;110(12):1149-54. doi: 10.1007/s00347-012-2676-y. Ophthalmologe. 2013. PMID: 24337206 Review. German. - Remodeling of the Lamina Cribrosa: Mechanisms and Potential Therapeutic Approaches for Glaucoma.
Strickland RG, Garner MA, Gross AK, Girkin CA. Strickland RG, et al. Int J Mol Sci. 2022 Jul 22;23(15):8068. doi: 10.3390/ijms23158068. Int J Mol Sci. 2022. PMID: 35897642 Free PMC article. Review. - Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.
Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH. Lim KS, et al. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. Ophthalmology. 2008. PMID: 18452763 Free PMC article. Clinical Trial.